Companies Cryptocurrencies
NeuBase Therapeutics Inc
NeuBase Therapeutics Inc
Exchange: NasdaqCM
IPO Date:
CEO: Dr. Dietrich Stephan
Biotechnology Healthcare 🔗
  • NBSE
  • 0.96
  • 31457472
    market cap
  • 0.00759995
If you bought

shares of NeuBase Therapeutics Inc (NBSE) on
You would have made
Old Price $12 Current Price $12

NeuBase Therapeutics, Inc. engages in the development of drugs for patients with genetic neurological disorder. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 3 full-time employees. The firm’s development pipeline consists of several programs and indications at various stages of development. Its product pipeline includes Squalamine Lactate Ophthalmic Solution 0.2% (Squalamine, also known as OHR-102), SKS Sustained Release Ocular Drug Delivery Platform Technology, Animal Model for Dry- Age-Related Macular Degeneration (AMD) and Non-Ophthalmology Assets. OHR-102 is a therapeutic product that provides a non-invasive therapy to improve vision outcomes. The SKS sustained release technology is designed to develop drug formulations for ocular disease. In the Company’s animal model for dry-AMD, mice are immunized with a carboxyethylpyrrole, which is bound to mouse serum albumin.

Address: 700 Technology Dr Pittsburgh PENNSYLVANIA 15219

Stay updated.